The Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI).

Trial Profile

The Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms OCTDESI
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 19 Apr 2011 Planned end date changed from 1 Mar 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 19 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Actual number of patients (60) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top